# Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)

> **NCT04541043** · PHASE3 · COMPLETED · sponsor: **Calliditas Therapeutics AB** · enrollment: 119 (actual)

## Conditions studied

- Primary IgA Nephropathy

## Interventions

- **DRUG:** Nefecon 16mg daily

## Key facts

- **NCT ID:** NCT04541043
- **Lead sponsor:** Calliditas Therapeutics AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-17
- **Primary completion:** 2024-02-26
- **Final completion:** 2024-02-26
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04541043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04541043, "Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04541043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*